Related Experiment Video

Updated: Aug 15, 2026

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

RCC Immune Microenvironment Subsequent to Targeted Therapy: A Friend or a Foe?

Wenjin Chen1, Xiuwu Pan1, Xingang Cui1

  • 1Department of Urology, The Third Affiliated Hospital of Second Military Medical University, Shanghai, China.

Frontiers in Oncology
|October 29, 2020
PubMed

Insights

Targeted therapies improve survival for advanced renal cell carcinoma (RCC), but drug resistance persists. Understanding the tumor microenvironment (TME) and its immune interactions is key for effective treatment strategies.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Renal cell carcinoma (RCC) exhibits significant tumor heterogeneity across subtypes.
  • Targeted therapies have improved outcomes for advanced RCC since 2006, yet complete responses remain limited due to drug resistance.
  • Emerging evidence links treatment outcomes to complex interactions between immune responses and suppressors within the tumor microenvironment (TME).

Purpose of the Study:

  • To comprehensively review the tumor microenvironment (TME) in renal cell carcinoma.
  • To summarize TME alterations induced by targeted therapies.
  • To explore the synergy between targeted therapy and immunotherapy for advanced RCC.

Main Methods:

  • Literature review of targeted therapies and immunotherapies for renal cell carcinoma.
  • Analysis of studies investigating the tumor microenvironment (TME) and its role in drug resistance.
  • Synthesis of evidence on immune responses and suppressors in the context of RCC treatment.

Main Results:

  • Targeted therapies have shown efficacy in advanced RCC but face challenges with drug resistance.
  • The tumor microenvironment (TME) plays a critical role in mediating responses and resistance to targeted treatments.
  • Cross-talk between immune components and targeted therapy is increasingly recognized as crucial.

Conclusions:

  • Further understanding of the tumor microenvironment (TME) is essential for overcoming targeted therapy resistance in RCC.
  • Optimizing treatment strategies may involve combining targeted therapies with immunotherapies.
  • Tailoring treatment based on TME characteristics holds promise for improving complete response rates in advanced RCC.
Keywords:
immune cellsimmunotherapyrenal cell carcinomatargeted therapytumor microenvironment

More Related Videos

Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors08:32

Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors

Published on: June 7, 2018

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
866